Aytu BioPharma delivered the kind of quarter that transition stories need: a loss of $0.05 per share against a consensus estimate of -$0.22, a 77.3% earnings surprise, and revenue of $16.11 million that beat the $11.55 million consensus by 39.4%. Earnings grew 80.8% year over year and revenue grew 6.4%, ending a string of declining quarters. On a GAAP basis the fiscal fourth quarter was essentially break-even, with a net loss of less than $0.1 million versus a $19.8 million loss a year ago, though that prior-year figure carried $8.3 million of impairment and a $9.9 million derivative warrant charge. The more meaningful signal is that adjusted EBITDA swung back to positive $0.5 million from negative $2.8 million in the third quarter.

The quality of the beat is better than the usual small-cap pharma surprise, because it was driven by volume rather than one-time items. EXXUA, in its first full launch quarter, generated $3.9 million in net revenue versus $2.4 million in the prior quarter, with more than 3,300 prescriptions written — more than double the 1,398 in Q3 — and a clean monthly ramp from 973 in April to 1,261 in June, then 1,377 in July and 1,408 in August. Unique prescribers reached nearly 1,200 launch-to-date, up from roughly 450 a quarter earlier and about 100 at launch. Management emphasized that adoption is broadening across territories rather than concentrating in a few heavy writers, and shipments rose nearly 40% sequentially to roughly 4,600 units. Consolidated gross margin improved to 65% from 61% sequentially, and fiscal 2026 operating cash flow was a positive $3.3 million against negative $1.9 million the year prior.

That is the encouraging half. The central tension is that the funding source for the EXXUA launch is eroding. The ADHD Portfolio generated $10.4 million versus $13.1 million a year ago, and for the full year fell to $45.8 million from $57.6 million. Pediatric revenue dropped to $5.1 million from $8.8 million for the year. Full-year revenue declined 13.3% to $57.6 million and full-year adjusted EBITDA swung to negative $3.7 million from positive $9.2 million. The fourth-quarter sequential rebound in both legacy portfolios — ADHD to $10.4 million from $9.1 million on better gross-to-net, Pediatric to $1.8 million from $0.9 million as supply normalized — is real, but management explicitly declined to call it a return to sustained growth. Investors should take that caution at face value; Teva has not yet launched a Cotempla generic despite a July 1 permitted date, which is upside to the current run-rate but also a clearly identified future headwind.

The call added execution nuance that the press release did not. The field force was cut to a low of 32 reps in July from 43 at the end of March before rebuilding to roughly 42, creating coverage gaps management said are still being filled — a self-inflicted disruption during the most sensitive phase of a launch. Rep productivity nonetheless more than doubled to roughly 43 prescriptions per rep per month in July from about 18 in March, and management laid out an expansion path toward 45-plus territories with illustrative annual run-rate math scaling with productivity. Reimbursement has been better than modeled, with net selling price running materially above initial launch assumptions and government payers growing toward 20-25% of the mix, but management repeatedly cautioned that favorable gross-to-net realization may not hold. Depth of adoption is the other open question: many prescribers have used EXXUA on only one or two patients.

Forward expense framing is where the near-term math gets harder. Fiscal 2027 gross operating expenses were framed at roughly $49-54 million, above the prior approximately $50 million reference, driven by about $6 million of sales and marketing spend deferred out of fiscal 2026. Management flagged lower adjusted EBITDA and cash flow in the first half of fiscal 2027 from that deferred spend, PDUFA fees and seasonal ADHD softness. In other words, part of the fourth quarter's positive EBITDA was borrowed from a spending delay, and it is coming due. Cash ended at $26.3 million versus $31.0 million a year ago, with the warrant restructuring in March cutting derivative liabilities by $26.4 million and lifting equity to $35.3 million.

The market has not been generous. Shares trade at $2.13, down 7.6% since the open following the prior report, about 10.8% below the $2.38 200-day moving average, 13.6% off the $2.46 inter-earnings high and 12.4% above the $1.89 low set on September 16. Earnings Whispers investor sentiment improved meaningfully, from -0.6476 to -0.2647, but remains negative — expectations rose with the launch data yet stopped well short of enthusiasm. The Earnings Whispers trend signals remain mostly negative, with price, sequential growth and AVWAP still weak while momentum has turned positive.

The bottom line is that Aytu produced its most convincing EXXUA quarter yet, with a large double beat, positive adjusted EBITDA and prescription momentum that has continued into September, but the story now hinges on whether EXXUA scales faster than the ADHD franchise erodes — and the deferred spend, rebuilt sales force and first-half fiscal 2027 profitability dip mean the next two quarters will likely look worse before the leverage management describes becomes visible.